Included in the agreement are ranibizumab-nuna 0.05 mL injection (BYOOVIZ), referencing LUCENTIS (ranibizumab), and ...

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it has entered into a ...

DelveInsight’s, “Multiple Sclerosis Pipeline Insight 2025” report provides comprehensive insights about 75+ companies and 80+ ...

Boston conference will explore strategic partnering, device innovation, and delivery solutions for emerging therapeutics.

The awards will be handed out at a gala event scheduled for October 9 at New York City’s Cipriani Wall Street.

Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus erythematosus (SLE) have been revealed, and have not disappointed.